Moleculin Biotech
MBRX
7 hedge funds and large institutions have $1.95M invested in Moleculin Biotech in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
88% more capital inflows, than outflows
Capital inflows: $348K | Capital outflows: $185K
17% more funds holding
Funds holding: 6 → 7 (+1)
0.66% more ownership
Funds ownership: 4.95% → 5.6% (+0.66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu KCG Holdings
New York
|
+$131K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.5K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$43.5K |
| 5 |
Two Sigma Securities
New York
|
+$43.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$117K |
| 2 |
BlackRock
New York
|
-$21K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 4 |
Goldman Sachs
New York
|
-$20K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$4K |
MBRX Hedge Fund Activity: Q2 2017 in Review
7 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2017, worth a combined $1.95M — up 112% from $918K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MBRX positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $131K. The largest seller was Sabby Management, exiting entirely with an estimated $117K sold.
- 7 institutional investors held Moleculin Biotech (MBRX) as of Q2 2017, up from 6 in Q1 2017.
- Funds reported $1.95M of Moleculin Biotech stock for Q2 2017, up 112% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q2 2017 and 1 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q2 2017 was Virtu KCG Holdings, an estimated $131K added.
- The largest Moleculin Biotech seller in Q2 2017 was Sabby Management, an estimated $117K sold.
Based on aggregated 13F filings for Q2 2017.